Imperial College Healthcare Nhs Trust

AI could enhance IVF success by identifying optimal follicle sizes for hormone injections, potentially increasing birth rates. Research by Imperial College London and others suggests targeting intermediate-sized follicles (13mm-18mm) improves egg retrieval. An AI tool for personalized IVF treatment is planned, aiming to support clinical decisions and improve outcomes.

AI boosts IVF success by identifying optimal follicle sizes for hormone injections, potentially increasing mature egg retrieval and birth rates. This innovation could personalize IVF, improving outcomes for couples facing infertility, amidst rising treatment costs and access challenges.

Bayer is preparing to file elinzanetant for menopause-related VMS treatment, following positive phase 3 trial results. It aims to compete with Astellas' Veozah, despite Veozah's slow market uptake due to HRT's cost-effectiveness and reduced side effect fears. VMS affects up to 80% of menopausal women, highlighting the need for new treatments.

AI analysis suggests IVF success improves when egg collection starts at specific follicle sizes (13-18mm), potentially increasing mature eggs retrieved and live births. This approach, using explainable AI, could personalize IVF treatment, enhancing decision-making and outcomes for couples facing infertility.

AI aids IVF by identifying optimal follicle sizes (13-18mm) for hormone injections, improving mature egg retrieval and birth rates. Researchers aim to develop an AI tool for personalized IVF treatment, enhancing decision-making and outcomes.

An AI model predicts high blood pressure and complications from ECGs, aiding early intervention. Clinical trials at Imperial College Healthcare NHS Trust aim to validate its use for patient benefit, potentially reducing risks through lifestyle changes.

PDS Biotechnology announces a Key Opinion Leader event on Dec 17, 2024, to discuss HPV16-positive HNSCC and the VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab. Panelists include Dr. Francis Worden and Dr. Kevin Harrington, moderated by Dr. Kirk Shepard.

Philips received FDA 510(k) clearance for remote scanning and protocol management on ROCC, enabling real-time expert assistance on MR and CT systems, enhancing efficiency and patient care.

ROCC, a multi-vendor, multi-modality imaging solution, enhances scanning throughput by 9% and ensures zero exam recalls. It enables real-time remote editing of MR and CT scanner consoles, facilitating efficient patient care. ROCC will be showcased at RSNA 2024 in Chicago.